warfarin tablets + Edoxaban tablets (high dose regimen-60mg) + Edoxaban tablets (low dose regimen-30mg) + placebo warfarin + placebo edoxaban
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Stroke
Conditions
Stroke, Atrial Fibrillation, Embolism
Trial Timeline
Nov 1, 2008 → May 1, 2013
NCT ID
NCT00781391About warfarin tablets + Edoxaban tablets (high dose regimen-60mg) + Edoxaban tablets (low dose regimen-30mg) + placebo warfarin + placebo edoxaban
warfarin tablets + Edoxaban tablets (high dose regimen-60mg) + Edoxaban tablets (low dose regimen-30mg) + placebo warfarin + placebo edoxaban is a phase 3 stage product being developed by Daiichi Sankyo for Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT00781391. Target conditions include Stroke, Atrial Fibrillation, Embolism.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00781391 | Phase 3 | Completed |
Competing Products
20 competing products in Stroke
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SPT-07A injection | Sinopharm | Phase 3 | 76 |
| Osmotic drugs | Sinopharm | Pre-clinical | 22 |
| Aspirin, Clopidogrel | Yuhan | Pre-clinical | 23 |
| DS-1040b + Placebo | Daiichi Sankyo | Phase 1/2 | 41 |
| SUN13837 + placebo | Daiichi Sankyo | Phase 2 | 52 |
| DS-1040b + Aspirin | Daiichi Sankyo | Phase 1 | 33 |
| piclozotan low dose + placebo + piclozotan high dose | Daiichi Sankyo | Phase 2 | 52 |
| DS1040b + Placebo | Daiichi Sankyo | Pre-clinical | 23 |
| Pharmacological intensification based on olmesartan | Daiichi Sankyo | Phase 2 | 52 |
| YM872 (zonampanel), t-PA (alteplase) | Astellas Pharma | Phase 2 | 52 |
| ASP2246 | Astellas Pharma | Phase 1/2 | 41 |
| Neu2000KWL + Neu2000KWL + Neu2000KWL + Placebos | Sun Pharmaceutical | Phase 2 | 52 |
| XY03-EA + XY03-EA Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| Redasemtide + Placebo | Shionogi | Phase 2 | 52 |
| Statin | Shionogi | Approved | 85 |
| Alteplase | Kyowa Kirin | Approved | 85 |
| ONO-2506 + ONO-2506 + ONO-2506 | Ono Pharmaceutical | Phase 2/3 | 65 |
| Abciximab | Eli Lilly | Phase 3 | 77 |
| Abciximab | Eli Lilly | Phase 3 | 77 |
| SB623 Implant (2.5M) + SB623 Implant (5.0M) | Sumitomo Pharma | Phase 2 | 52 |